Switch theme
Sign up to access all valuation multiples
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
1993
225
LTM Revenue $22.8M
LTM EBITDA -$64.9M
$52.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
FibroGen has a last 12-month revenue of $22.8M and a last 12-month EBITDA of -$64.9M.
In the most recent fiscal year, FibroGen achieved revenue of $29.6M and an EBITDA of -$142M.
FibroGen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See FibroGen valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $148M | $29.6M | XXX | XXX | XXX |
| Gross Profit | $120M | $129M | XXX | XXX | XXX |
| Gross Margin | 82% | 435% | XXX | XXX | XXX |
| EBITDA | -$261M | -$142M | XXX | XXX | XXX |
| EBITDA Margin | -177% | -481% | XXX | XXX | XXX |
| Net Profit | -$294M | -$284M | XXX | XXX | XXX |
| Net Margin | -199% | -960% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, FibroGen's stock price is $0.
FibroGen has current market cap of $30.3M, and EV of $52.9M.
See FibroGen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $52.9M | $30.3M | XXX | XXX | XXX | XXX | $-0.51 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, FibroGen has market cap of $30.3M and EV of $52.9M.
FibroGen's trades at 2.3x LTM EV/Revenue multiple, and -0.8x LTM EBITDA.
Analysts estimate FibroGen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for FibroGen and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $52.9M | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | -0.4x | XXX | XXX | XXX |
| P/E | -0.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpFibroGen's NTM/LTM revenue growth is -72%
FibroGen's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.6M for the same period.
Over next 12 months, FibroGen's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate FibroGen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for FibroGen and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -80% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -481% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -46% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -553% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 323% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 490% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
FibroGen acquired XXX companies to date.
Last acquisition by FibroGen was XXXXXXXX, XXXXX XXXXX XXXXXX . FibroGen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was FibroGen founded? | FibroGen was founded in 1993. |
| Where is FibroGen headquartered? | FibroGen is headquartered in United States of America. |
| How many employees does FibroGen have? | As of today, FibroGen has 225 employees. |
| Who is the CEO of FibroGen? | FibroGen's CEO is Mr. Thane Wettig. |
| Is FibroGen publicy listed? | Yes, FibroGen is a public company listed on NAS. |
| What is the stock symbol of FibroGen? | FibroGen trades under FGEN ticker. |
| When did FibroGen go public? | FibroGen went public in 2014. |
| Who are competitors of FibroGen? | Similar companies to FibroGen include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of FibroGen? | FibroGen's current market cap is $30.3M |
| What is the current revenue of FibroGen? | FibroGen's last 12-month revenue is $22.8M. |
| What is the current EBITDA of FibroGen? | FibroGen's last 12-month EBITDA is -$64.9M. |
| What is the current EV/Revenue multiple of FibroGen? | Current revenue multiple of FibroGen is 2.3x. |
| What is the current EV/EBITDA multiple of FibroGen? | Current EBITDA multiple of FibroGen is -0.8x. |
| What is the current revenue growth of FibroGen? | FibroGen revenue growth between 2023 and 2024 was -80%. |
| Is FibroGen profitable? | Yes, FibroGen is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
